2021 ACOG Annual Clinical and Scientific Meeting

Efficacy, safety of levonorgestrel-releasing intrauterine system sustained at 6–7 years

Roshini Claire Anthony, 20210608180001

Year 6 and 7 cumulative data from the Mirena Extension Trial suggest that the efficacy and safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) as a contraceptive method is maintained over this time frame.

Mifepristone-misoprostol combo shortens time to delivery during late pregnancy loss

Elvira Manzano, 20210527105000

Administration of mifepristone, followed by misoprostol, shortened induction-to-delivery intervals in women who lost their babies during the third trimester of pregnancy compared with misoprostol alone, results of a systematic review has shown.

Ibrexafungerp shows promise as first non-azole treatment for vulvovaginal candidiasis

Roshini Claire Anthony, 20210521180001

The novel oral triterpenoid antifungal ibrexafungerp demonstrated superiority over placebo in reducing signs and symptoms of vulvovaginal candidiasis, according to results of the phase III VANISH-306 trial presented at ACOG 2021.

Lack of reproductive aged women in COVID-19 trials has long-ranging effects

Roshini Claire Anthony, 20210519180001

Women of reproductive age are often excluded from COVID-19 vaccine and treatment clinical trials, which could hinder their access to beneficial treatments, according to a study presented at the recent ACOG 2021 meeting.